May 28, 2021 -- Sanofi and GlaxoSmithKline started their phase III trial to assess the safety, efficacy, and immunogenicity of their recombinant-protein COVID-19 vaccine candidate.
The trial will evaluate how the vaccine targets the original variant, the B.1.351 variant, and other circulating variants.
The enrollment follows positive results from the phase II trial, which showed the vaccine produced strong rates of neutralizing antibody responses in all adult age groups. Pending positive phase III outcomes and regulatory reviews, the vaccine may be approved by the last quarter of 2021.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
